| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
|
N Engl J Med
|
1986
|
3.22
|
|
2
|
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation.
|
Blood
|
1999
|
2.97
|
|
3
|
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.
|
N Engl J Med
|
1989
|
2.61
|
|
4
|
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.
|
Blood
|
2001
|
2.04
|
|
5
|
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
|
Bone Marrow Transplant
|
2006
|
1.84
|
|
6
|
Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial.
|
Blood
|
1989
|
1.65
|
|
7
|
Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial.
|
Br J Haematol
|
1989
|
1.57
|
|
8
|
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.
|
Blood
|
1994
|
1.57
|
|
9
|
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
|
Leukemia
|
2009
|
1.38
|
|
10
|
Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease.
|
Blood
|
1986
|
1.30
|
|
11
|
NCCN Practice Guidelines for Breast Cancer.
|
Oncology (Williston Park)
|
2000
|
1.22
|
|
12
|
Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor.
|
Blood
|
1993
|
1.08
|
|
13
|
A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
|
Bone Marrow Transplant
|
2000
|
1.00
|
|
14
|
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
|
Biol Blood Marrow Transplant
|
1999
|
0.99
|
|
15
|
CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons.
|
Blood
|
1992
|
0.98
|
|
16
|
Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens.
|
J Clin Oncol
|
1993
|
0.98
|
|
17
|
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
|
Bone Marrow Transplant
|
2000
|
0.93
|
|
18
|
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
|
J Clin Oncol
|
1993
|
0.93
|
|
19
|
Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.
|
Bone Marrow Transplant
|
1994
|
0.92
|
|
20
|
Changing trends in marrow transplantation for aplastic anemia.
|
Bone Marrow Transplant
|
1992
|
0.91
|
|
21
|
Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials.
|
Blood
|
1988
|
0.90
|
|
22
|
Late complications of allogeneic and autologous marrow transplantation.
|
Bone Marrow Transplant
|
1992
|
0.90
|
|
23
|
Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung.
|
Cancer Treat Rep
|
1983
|
0.89
|
|
24
|
Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation.
|
Transplantation
|
1986
|
0.89
|
|
25
|
Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor.
|
Bone Marrow Transplant
|
1994
|
0.85
|
|
26
|
Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
|
Bone Marrow Transplant
|
2003
|
0.84
|
|
27
|
Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival.
|
Bone Marrow Transplant
|
1991
|
0.84
|
|
28
|
Safety of granulocyte colony-stimulating factor in normal donors.
|
Curr Opin Hematol
|
2001
|
0.83
|
|
29
|
Severe central nervous system toxicity associated with the infusion of cryopreserved PBSC components.
|
Cytotherapy
|
1999
|
0.82
|
|
30
|
Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?
|
Biol Blood Marrow Transplant
|
1997
|
0.82
|
|
31
|
Study on contribution of genetically marked peripheral blood repopulating cells to hematopoietic reconstitution after transplantation.
|
Hum Gene Ther
|
1994
|
0.81
|
|
32
|
Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.
|
Transplant Proc
|
1987
|
0.80
|
|
33
|
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
|
Med Pediatr Oncol
|
2000
|
0.79
|
|
34
|
Marrow transplantation for severe aplastic anemia and thalassemia major.
|
Semin Hematol
|
1991
|
0.79
|
|
35
|
Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine.
|
Leuk Res
|
1985
|
0.79
|
|
36
|
Preparation of red-blood-cell-depleted marrow for ABO-incompatible marrow transplantation by density-gradient separation using the IBM 2991 blood cell processor.
|
Exp Hematol
|
1987
|
0.78
|
|
37
|
Autologous bone marrow transplantation for acute lymphoblastic leukemia.
|
Bone Marrow Transplant
|
1993
|
0.78
|
|
38
|
Engraftment in 86 with patients lymphoid malignancy after autologous marrow transplantation.
|
Bone Marrow Transplant
|
1989
|
0.78
|
|
39
|
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia.
|
Blood
|
1992
|
0.77
|
|
40
|
Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia.
|
Blood
|
1994
|
0.76
|
|
41
|
Autologous marrow transplantation in patients with acute nonlymphocytic leukemia in first remission.
|
Exp Hematol
|
1985
|
0.76
|
|
42
|
Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease.
|
Hum Gene Ther
|
1997
|
0.75
|
|
43
|
Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia.
|
Bone Marrow Transplant
|
1993
|
0.75
|
|
44
|
Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation.
|
Bone Marrow Transplant
|
1988
|
0.75
|
|
45
|
Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
1998
|
0.75
|
|
46
|
High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer.
|
Bone Marrow Transplant
|
2000
|
0.75
|